Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug505 | Background questionnaire Wiki | 1.00 |
| drug1019 | Confinement and Communication During the COVID-19 Pandemic Wiki | 1.00 |
| drug2335 | Mental Health questionnaire Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3033 | Post Traumatic Stress Disorder questionnaire (PTSD-8) Wiki | 1.00 |
| drug1634 | Generalized Anxiety Disorder-7 (GAD 7) Wiki | 1.00 |
| drug1449 | Experiences in Close Relationship Scale questionnaire (ECR-S) Wiki | 1.00 |
| drug2830 | Patient Health Questionnaire (PHQ-9) Wiki | 1.00 |
| drug1909 | Impact of COVID-19 questionnaire Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D040921 | Stress Disorders, Traumatic NIH | 0.18 |
| D001008 | Anxiety Disorders NIH | 0.14 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The overall objective of this project is to develop an emergent treatment protocol using adoptive T-cell therapy for the treatment of severe COVID-19. The central hypothesis is that SARS-CoV-2 specific T cells from convalescent donors who have recovered from COVID-19 can be manufactured expeditiously for the treatment of severe SARS-CoV-2 infections.
Description: Success of SARS-CoV-2 specific T cell manufacturing is defined as production of >200,000 T cells per donor. The success rate will be summarized descriptively.
Measure: Success rate in production of SARS-CoV-2 specific T cells from convalescent donor Time: Two weeks (The expected duration of donor participation is 2 weeks)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports